Clinical Trials Logo
  1. Home
  2. Cardiovascular Risk
  3. NCT06118281

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack — ARTEMIS  

Cardiovascular Risk Clinical Trial

Official title:
ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction

Clinical Trial Summary

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06118281
Study type Interventional
Source Novo Nordisk A/S
Contact Novo Nordisk
Phone (+1) 866-867-7178
Email clinicaltrials@novonordisk.com
Status Not yet recruiting
Phase Phase 3
Start date June 25, 2024
Completion date September 3, 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT01139827 - Association Between Framingham Risk Score, hsCRP and Vascular Inflammation: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography N/A
Recruiting NCT05767073 - LIVES: Personalized Lifestyle Intervention for Patients With Depression N/A
Completed NCT04626505 - Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan. Phase 2
Completed NCT00856882 - The Effects of Soy Protein and Isoflavones on Glycemic Control, Insulin Sensitivity and Cardiovascular Risk Factors N/A
Completed NCT04330937 - Clinical Trial on the Effectiveness of Citrolive N/A
Completed NCT01781416 - Level of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk N/A
Completed NCT01475513 - Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women Phase 4
Enrolling by invitation NCT06122961 - Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
Completed NCT04506749 - To Evaluate the Efficacy of a Nutraceutical in Reducing Cardiovascular Risk in Healthy Subjects N/A
Completed NCT03412175 - CREATION Health Lifestyle Intervention N/A
Completed NCT02144922 - Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients Phase 4
Completed NCT00921752 - C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS) N/A
Completed NCT00697580 - Strength and Nutrition Outcomes for Latino Adolescents N/A
Enrolling by invitation NCT04450914 - Implementing Shared Decision Making (SDM) For Individualized CV Prevention (SDM4IP) N/A
Completed NCT01003574 - Evaluation of Cardiovascular Health Outcomes Among Survivors N/A
Completed NCT01441323 - Strength Training and Nutrition Development for African American Youth N/A
Completed NCT01103648 - Effect of Simvastatin and Ezetimibe on Lipid and Inflammation N/A
Completed NCT01015092 - Cardiovascular Risk Evaluation and Antiretrovirals in HIV N/A
Not yet recruiting NCT05882266 - The Role of Plant-Based Omega-3 Fatty Acids and Molecular Characterisation in Individuals With Cardiovascular(CVD) Risk N/A
Completed NCT00988754 - School Based Health Promotion Program in Secondary Schools N/A